JnJ
According to a recent Reuters article, the FDA has granted approval to Johnson & Johnson for its antibody-based therapy called Talvey. The drug is designed to treat a challenging type of blood cancer by leveraging bispecific antibodies that facilitate the immune system's attack on cancer cells. Talvey will be priced at $45,000 per month, with estimated costs ranging from $270,000 to $360,000 for a six to eight-month treatment duration.
